Accelerating the timeline to tox material can significantly enhance the drug development process, enabling faster IND submissions and providing crucial time savings for toxicology studies.
With more than 12 years of cell and gene therapy research and commercialization, GC Cell fully understands the unique challenges around cell and gene therapy development and manufacturing.
Explore how expert CMC strategies and clinical manufacturing experience can lay the groundwork for the successful commercialization of advanced cell therapies.
With experience in the biopharma and medical device industries, our team provides support for all product development phases from early clinical to post-commercial life cycle management.
Whether you are just beginning your development or are advancing toward commercialization, we provide the global laboratory infrastructure necessary for success.
Our deep expertise in cell line development, process optimization, and scalable GMP manufacturing ensures high-yield, high-quality protein production tailored to your therapeutic goals.
With over 30 years of GMP manufacturing expertise, we offer dedicated capacity for clinical and commercial gene therapy batches, using advanced AAV platforms and proprietary cell lines.
The 132M HC sets the standard for performance, precision, and reliability. This wrap-around labeler applies labels to cylindrical products with the utmost accuracy at the highest performance.
Advancing safe and effective oligonucleotide delivery requires microfluidic mixing to produce lipid nanoparticles with precise size control, stability, and scalability.
Katie Jorgensen introduces ElevateBio BaseCamp's path to commercial readiness in cell therapy, highlighting key strategies for scaling, with a focus on staffing, training, and preparation for 2025.
High titer, high yield, high-quality, and de-risked lentivirus manufacturing. The ultimate solution to bring your lentivirus-based cell or gene therapy to GMP in <12 months.
